Alec Vahanian, FESC, FRCP Bichat Hospital, Paris

Slides:



Advertisements
Similar presentations
Developing the Nurse Coordinator Role
Advertisements

” سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم “
Trans-catheter Aortic Valve Implantation Should we all be doing this? Dr Philip MacCarthy BSc PhD FRCP Consultant Cardiologist King’s College Hospital,
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve ® has been approved. The CoreValve ® System is not currently approved in the USA,
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
The Structural Heart Disease Program your partners for advanced interventional cardiology Structural Heart Disease is a new branch of cardiology involving.
Dr Martyn Thomas Director of Cardiac Services Guys and St Thomas NHS Foundation Trust A Member of Kings Health Partners London.
TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation
Dr R H Stables Cardiothoracic Centre Liverpool, UK Thoracic Aortic Stent Grafting.
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Trancatheter Aortic Valve Implantation (TAVI)
VIRTUAL SIMULATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION Jenna Smetana and Jessica Sider, Swanson School of Engineering THE TAVI PROCEDURE IS FEASIBLE.
EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.
Greater New York Geriatric Cardiology Consortium: Valve Disease in Older Adults Allan Schwartz, MD Columbia University Medical Center New York Presbyterian.
G. Michael Deeb, MD On Behalf of the CoreValve US Investigators
Patients the Surgeon Should Refer for TAVR
TAVR in Patients With Chronic Kidney Disease
VSD post TAVR: Mechanisms, Presentation and Management
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
Extending the Boundaries of TAVR: Future Directions
Trans- catheter aortic valve replacement vs
TAVR Medtronic CoreValve® Subclavian Approach Clinical Data
Is Transoesophageal Echocardiography during TAVR Essential?
Imaging and Quantification of Aortic Regurgitation after TAVI
Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators
Optimizing Valve Sizing: Role of CT vs. Echo
Patient Selection for TAVI:
US Pivotal Trial: Update
TAVR Addressing Real-Life Issues CRT 2013 Washington DC
Are we ready to perform TAVI in Intermediate Risk Patients?
Updates From NOTION: The First All-Comer TAVR Trial
Structural Heart Live Cases
Are we ready for expanding TAVI indications to moderate and low risk
TAVR-Endocarditis Tarek Chami, MD
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
Joseph E. Bavaria, M.D. Roberts-Measey Professor and
TAVR – The Trans-carotid Approach
TAVR Requirements for the Cath Lab
Trans-Apical Aortic Valve Implant:
The Spanish Data Bank PEGASO M. Martínez-Sellés
30 Day Outcomes from the SOURCE XT TAVI Post Approval Study
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
University of Pennsylvania
Columbia University Medical Center Cardiovascular Research Foundation
Optimizing Valve Sizing: Role of CT vs. Echo
5th Meeting on Acute Cardiac Care and Emergency Medicine, 2016 Vilnius
Giuseppe Tarantini MD, PhD
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
TAVI „Catch me if you can!“
Panel Discussion: What Should Be the Optimal Design for Percutaneous Aortic Valve Therapy? Raoul Bonan, MD Institut de Cardiologie de Montreal.
Updates From SURTAVI in Intermediate Risk Patients
Longevity of transcatheter and surgical bioprosthetic aortic valves in patients with severe aortic stenosis and lower surgical risk Lars Sondergaard,
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
Michael Mack, M.D. Dallas, TX February 21, 2010
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
Larry L. Wood Corporate Vice President Edwards Lifesciences
Balloon-Expandable Transcatheter Valve System : OUS Data
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
Risk Stratification of Severe, Symptomatic Aortic Stenosis Patients
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Cardiovacular Research Technologies
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
Coronary Revascularization and TAVR
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Presentation transcript:

Alec Vahanian, FESC, FRCP Bichat Hospital, Paris Assembling the “Heart team” : Dynamics , Decision making and Collaboration During Procedures Alec Vahanian, FESC, FRCP Bichat Hospital, Paris Put the title of french society of cardiology ,see with stephanie

Alec Vahanian, MD Honoraria: Valtech Edwards Lifesciences Medtronic Abbott

(EACTS/ESC/EAPCI Position Statement, Eur Heart J, 2008; 29: 1463-1470, Euro intervention a rajouter chaque fois (EACTS/ESC/EAPCI Position Statement, Eur Heart J, 2008; 29: 1463-1470, Eur J Cardiothorac Surg 34 (2008) 1-8, Eurointerv. 2008; 4:193-199) 4

The “Heart Team” A group of valve specialists who collaborate to: Select the most appropriate procedure Perform the procedures Evaluate the results (EACTS/ESC/EAPCI Position Statement, Eur Heart J, 2008; 29: 1463-1470, Eur J Cardiothorac Surg 34 (2008) 1-8, Eurointerv. 2008; 4:193-199)

Transcatheter Aortic Valve Implantation The « Heart Team » CARDIOLOGISTS SURGEONS Anesthesiologists Transcatheter Aortic Valve Implantation Other specialists: Geriatricians …… Imaging specialists (Echo, CT, MRI) With expertise in the treatment of valve disease EACTS/ESC/EAPCI Position Statement, Eur Heart J, 2008; 29: 1463-1470, Eur J Cardiothorac Surg 34 (2008) 1-8

Risk-Benefit Assessment Decision-making for intervention is multifactorial: Prognosis according to severity and consequences of valvular disease Risks and late consequences of intervention Patient life expectancy and quality of life Patient wishes after information Local resources, in particular results of surgery

Predicted mortality (STS ) :11.7% Observed operative mortality : 6.4% Risk Scores Good discrimination (low vs. high risk) But poor calibration (predicted vs. observed risk) (Iung Heart 2008;94:519-24) PARTNER A Predicted mortality (STS ) :11.7% Observed operative mortality : 6.4% (Dewey et al. JTCS 2008;135:180-7) (Brown et al. JTCS 2008;136:566-71)

Assessment of Frailty Surgeon’s eye-ball test and beyond !!!! In the past, surgeons have determined whether patients are frail or not frail based on gross physical examination and clinical covariates commonly associated with frailty (age, gender, BMI, comorbid conditions) • The patient just “looks too frail” • However, there are potential issues with subjective assessment: • Even greater challenge in the AS/heart failure population • Surgeon dependent: wide variation among evaluating physicians because it’s purely subjective. • May be based on chronologic age alone which is not always appropriate. 9

Assessment of Extra-Cardiac Factors Frailty (Katz score + Ambulation Aid + Dementia) Neurological dysfunction (with functional impairment) Pulmonary disease (GOLD stage II) Peripheral vascular disease (including porcelain aorta) Renal disease (KDOQI Stage 3, GFR < 60 mL/min) Poor Metabolic state (high bilirubin, low albumin, Diabetes, hyponatraemia, PT …), BMI < 20, Liver failure (Child-Pugh)….

Conventional AVR Medical Rx (59%) Screening in Bichat among 603 High-risk Patients Referred for TAVI EuroSCORE ≥ 20% - STS PROM ≥ 10% / CI to AVR Conventional AVR 54 (9%) Medical Rx 195 (32%) TAVI 354 (59%) « Cohort C » 11

Needs Who Skills Cardiologists/ Clinical/ echocardiography Surgeons Surgeons/ Anesthesiologists/ Geriatricians Skills Clinical/ echocardiography Clinical

Risk-Benefit Assessment Decision-making for intervention is multifactorial: Prognosis according to the severity and consequences of valvular disease Risks and late consequences of intervention Patient life expectancy and quality of life Patient wishes after information Local resources, in particular results of surgery Feasibility of transcatheter intervention

Transcatheter Aortic Valve Implantation Multi-Modality Screening before Transcatheter Aortic Valve Implantation Measurement of aortic annulus When looking at the decision for implantation and the choice of prosthesis size based on TEE the decision would have changed in 40% of patients if MSCT was used (Messika-Zeitoun. J Am Coll Cardiol, 2010;55:186-94) Distance coronary – aortic valve Evaluation of calcium distribution

Other Contraindication LV apical thrombus Contrast echo, MSCT Dynamic subaortic obstruction Echo Severe organic MR is a contraindication but functional MR is not

Vascular Access Judgement based on the combination of : Conventional angio + MSCT Sagittal + transversal views Judgement based on the combination of : Minimal diameters 18 Fr: 6mm 22 Fr: 7mm 24 Fr: 8mm Calcification (grading) Tortuosity Choice of the approach

Needs Skills Who Clinical/ Cardiologists/ Surgeons echocardiography Echocardiography / CT/ MRI Who Cardiologists/ Surgeons Cadiologists/ Surgeons/ Geriatricians Cardiologists/ Radiologists/Surgeons

The “Heart Team” A group of valve specialists who collaborate to: Select the most appropriate procedure Perform the procedures Evaluate the results (EACTS/ESC/EAPCI Position Statement, Eur Heart J, 2008; 29: 1463-1470, Eur J Cardiothorac Surg 34 (2008) 1-8, Eurointerv. 2008; 4:193-199)

Where Should we Perform? In cardiology and cardiac surgery centers Make in specialised centres appear first then as it is 19

FRANCE 2 Procedural characteristics (84%) 74.7% 15.3% 9.9% (21%) (12%) (84%) General anesthesia, % 59 % Per-procedure TEE, % 60.7 % 74.7% (67%) Operative room Cath-lab Hybrid room

Echocardiography is Helpful in Monitoring the Procedure

New Systems for Navigation and Positioning during TAVI

Transfemoral Approach Percutaneous access + surgical closure Surgical access and closure Percutaneous access and closure (closure device)

Alternatives to the TF approach Transapical (Edwards Sapien) Subclavian (Medtronic CoreValve) Transaortic (Both)

« Complementary Techniques » Severe symptomatic AS Agreed high surgical risk Annular sizing Echo/CT/both Coronary sinus/LVOT suitable Re-evaluate surgical options 18-20 mm 20-25 mm 25-27 mm Proximal ascending aorta ≤40 mm (20-23 mm annuli) ≤ 43 mm (23-27 mm annuli) no Femoral sizing angio/CT/both Femoral>6mm yes no Femoral sizing angio/CT/both Fem ≥ 6 mm no yes no yes Axillary ≥ 6 mm Edwards Transapical Edwards Transfemoral CoreValve Transfemoral no yes or Direct Aortic Access CoreValve Transaxillary (Jilaihawi. JACC: Cardiovasc Int 2010;3:859-66.)

Traumatic Iliac Dissection Post-procedure angio Dissection Stenting Final Result

Rescue Surgery « Be prepared »

Needs Who Skills Cardiologists/surgeons Clinical /echocardiography Cardiologists/surgeons/ Geriatricians Cardiologists/surgeons/ radiologists Interventionists/ echocardiographists/ anesthesiologists/ surgeons/paramedical staff of cath lab Skills Clinical /echocardiography Clinical Echocardiography/CT Working in a sterile environment/valvular catheterization/balloon valvuloplasty/vascular access/peripheral intervention /valve surgery/cardiac assistance

Needs Who Skills Interventionists/ anesthesiologists/ surgeons/ paramedical staff of cath lab and/or Cardiologists/surgeons/ anesthesists/intensive care/EP specialists Skills Working in a sterile environment/Valvular catheterization/balloon valvuloplasty/vascular access/peripheral intervention/monitoring/valve surgery/Cardiac assistance Post operative care

Training Steps basic training Advanced skills Device specific skills Device training Advanced skills Disease or procedure-specific skills basic training Basic endovascular skills Basic surgical and valve disease skills 31

Accredited Programs vs Alternative Training Current pathway Cross training Bench training and Simulators Animal lab PCR / TCT / CRT /JIM / ICI ........... Industry sponsored postgraduate courses Scientific Societies sponsored postgraduate courses Accredited postgraduate residency or fellowship training program 32

The “Heart Team” A group of valve specialists who collaborate to: Select most appropriate procedure Perform it Evaluate the results

Evaluation of TAVI As well as enrolment in randomized clinical trials, data should be accumulated in registries with F.U. In centres performing TAVI, multidisciplinary meetings should be held to discuss indications, procedural techniques, and case outcomes. Hospitals should keep proof of close medico-surgical collaboration and maintain a log of all patients referred to TAVI for continuous evaluation of the programme (EACTS/ESC/EAPCI Position Statement, Eur Heart J, 2008; 29: 1463-1470, Eur J Cardiothorac Surg 34 (2008) 1-8, Eurointerv. 2008; 4:193-199)

Conclusions Team members must learn to collaborate, select the best candidates, perform the procedure and evaluate the results Institutional and individual training is necessary The appropriate environment must be available in terms of sterility, imaging, access to surgery and cardiac support

“We may have all come in different ships, but we’re in the same boat now” Martin Luther King, Jr.